Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemedFRA:CXM +0.46%85 EV-to-EBITDA is 17.21 as of Jul. 27, 2026, which is 11% below its 10-year median of 19.26. GuruFocus rates FRA:CXM with a GF Score™ of 85/100 and a GF Value™ of €572.28 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 509 Healthcare Providers & Services companies, Chemed ranks worse than 71.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Chemed's enterprise value is €6,157 Mil.
Chemed's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €358 Mil. Therefore, Chemed's EV-to-EBITDA for today is 17.21.
The historical rank and industry rank for Chemed's EV-to-EBITDA or its related term are showing as below:
FRA:CXM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.83 Med: 19.26 Max: 33.73
Current: 16.82
During the past 13 years, the highest EV-to-EBITDA of Chemed was 33.73. The lowest was 10.83. And the median was 19.26.
FRA:CXM's EV-to-EBITDA is ranked worse than 71.32% of 509
companies
in the Healthcare Providers & Services industry
Industry Median: 10.97
vs FRA:CXM: 16.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-27), Chemed's stock price is €438.00.
Chemed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €15.762. Therefore, Chemed's PE Ratio (TTM) for today is 27.79.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Chemed (FRA:CXM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Chemed's share price for today is €438.00.
Chemed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.762.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Chemed's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CXM vs PACS, LFST, UHS: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Chemed's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemed EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chemed's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chemed's EV-to-EBITDA falls into.
Chemed's current Enterprise Value is €6,157 Mil.
Chemed's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €358 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemed (FRA:CXM) has a EV-to-EBITDA of 17.21 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chemed. This is 11% below median its historical median of 19.26. Over the past decade, Chemed's EV-to-EBITDA has ranged from 10.83 to 33.73. According to the industry distribution chart, Chemed ranks #363 out of 509 companies in the Healthcare Providers & Services industry, placing it in the top 71.3%.
Is Chemed's EV-to-EBITDA too high?
Chemed's current EV-to-EBITDA of 17.21 is 11% below median its 10-year median of 19.26. Over the past 10 years, this metric has ranged from a low of 10.83 to a high of 33.73. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.97. Chemed's value of 17.21 is 56.9% above this industry median. Based on the distribution chart, Chemed ranks #363 out of 509 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Chemed has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's EV-to-EBITDA compare to PACS and LFST?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #363 out of 509 companies for EV-to-EBITDA. This places Chemed in the lower half of its industry. The industry median EV-to-EBITDA is 10.97. Chemed's value of 17.21 is 56.9% above this benchmark. Historically, Chemed's own EV-to-EBITDA has ranged from 10.83 to 33.73 over the past decade. While the company's 10-year median is 19.26 vs. the industry median of 10.97, Chemed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.97, based on 509 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current EV-to-EBITDA of 17.21 is 56.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Chemed. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current EV-to-EBITDA is 17.21, which is 11% below median its own 10-year median of 19.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Modestly Undervalued. The stock's GF Value™ is €572.28, compared to a current price of €438.00 — trading 23.5% below its estimated fair value. The current EV-to-EBITDA is 17.21, which is 11% below median its 10-year median of 19.26 and 56.9% above the Healthcare Providers & Services industry median of 10.97. Chemed's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Chemed (FRA:CXM), the current EV-to-EBITDA is 17.21 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemed (FRA:CXM) Overvalued in 2026?
Based on GuruFocus' analysis, Chemed stock appears to be undervalued.
The current stock price of €438.00 is trading 23.5% below its estimated GF Value™ of €572.28.
GuruFocus considers Chemed to be Modestly Undervalued.
Key valuation signals for FRA:CXM:
EV-to-EBITDA: 17.21 (11% below median its 10-year median of 19.26)
GF Value™: €572.28 vs. price of €438.00 (23.5% below fair value)
Industry Position: 56.9% above the Healthcare Providers & Services median (#363 of 509)
No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
85GF Score
Get the complete analysis for FRA:CXM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CXM has been successfully added to your 
